Varicella-zoster virus: Molecular virology and virus-host interactions

Current Opinion in Microbiology

Volumn 4, Issue 4, 2001, Pages 442-449

  Arvin, Ann M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS GLYCOPROTEIN;

CELL CULTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; REVIEW; VARICELLA ZOSTER VIRUS; VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS PATHOGENESIS;

HUMAN HERPESVIRUS 3;

EID: 0034894639     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(00)00233-2     Document Type: Review

References (52)

1. Stability of a varicella-zoster virus glycoprotein E epitope
2. Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice
3. Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates
4. Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR
5. Identification and mapping of single nucleotide polymorphisms in the varicella-zoster virus genome
6. Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity
7. Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype
8. Glycoprotein E of varicella-zoster virus enhances cell-cell contact in polarized epithelial cells
9. Characterization of varicella-zoster virus glycoprotein K (open reading frame 5) and its role in virus growth
10. Varicella-zoster virus Fc receptor component gl is phosphorylated on its endodomain by a cyclin-dependent kinase
11. Cytoplasmic domain signal sequences that mediate transport of varicella-zoster virus gB from the endoplasmic reticulum to the Golgi
12. Characterization of interaction of gH and gL glycoproteins of varicella-zoster virus: Their processing and trafficking
13. Influence of different cellular transcription factors on the regulation of varicella-zoster virus glycoproteins E (gE) and I (gl) UTR's activity
14. Trafficking of varicella-zoster virus glycoprotein gl: T(338)-dependent retention in the trans-Golgi network, secretion, and mannose 6-phosphate-inhibitable uptake of the ectodomain
15. Essential role played by the C-terminal domain of gl in the envelopment of varicella zoster virus in the trans-Golgi network: Interactions of glycoproteins with tegument
16. Viral proteins
17. Gene activation by varicella-zoster virus IE4 protein requires its dimerization and involves both the arginine-rich sequence, the central part, and the carboxyl-terminal cysteine-rich region
18. Nuclear accumulation of IE62, the varicella-zoster virus (VZV) major transcriptional regulatory protein, is inhibited by phosphorylation mediated by the VZV open reading frame 66 protein kinase
19. Physical interaction between two varicella zoster virus gene regulatory proteins, IE4 and IE62
20. The TATA motif specifies the differential activation of minimal promoters by varicella zoster virus immediate-early regulatory protein IE62
21. Highly purified recombinant varicella zoster virus thymidine kinase is a homodimer
22. Transcription factor Sp1 is involved in the regulation of varicella-zoster virus glycoprotein E
23. Open reading frame S/L of varicella-zoster virus encodes a cytoplasmic protein expressed in infected cells
24. Modulation of major histocompatibility class II protein expression by varicella-zoster virus
25. Varicella zoster virus retains major histocompatibility complex class I proteins in the Golgi of infected cells
26. Tropism of varicella-zoster virus for human CD4+ and CD8+ T-lymphocytes and epidermal cells in SCID-hu mice
27. The attenuation of the vaccine Oka strain of varicella-zoster virus and the role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse
28. The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse
29. No acute varicella-zoster virus replication in peripheral blood mononuclear cells during postherpetic neuralgia
30. Acyclovir treatment prevents varicella-zoster virus replication in PBMC during viremia
31. Quantitation of varicella-zoster virus DNA in whole blood, plasma, and serum by PCR and electrochemiluminescence
32. Infection of human T-lymphocytes with varicella-zoster virus: An analysis with viral mutants and clinical isolates
33. Varicella-zoster virus infection of a human CD4-positive T-cell line
34. Comparison of quantitations of viral load in varicella and zoster
35. Varicella-zoster virus proteins in skin lesions: Implications for a novel role of ORF29p in chickenpox
36. Latent varicella-zoster virus in human dorsal root ganglia
37. Varicella-zoster virus gene expression in latently infected and explanted human ganglia
38. Quantitation of latent varicella-zoster virus and herpes simplex virus genomes in human trigeminal ganglia
39. Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR
40. Comparison of primary sensitization of naive human T-cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination
41. IL-12, IFN-gamma, and TNF-alpha released from mononuclear cells inhibit the spread of varicella-zoster virus at an early stage of varicella
42. Frequencies of memory T-cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression
43. Prenatal diagnosis of congenital varicella syndrome and detection of varicella-zoster virus in the fetus: A case report
44. Neonatal varicella: A report of 26 cases
45. Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency
46. Analysis of immune responses to varicella zoster viral proteins induced by DNA vaccination
47. Differential neutralizing antibody responses to varicella-zoster virus glycoproteins B and E following naked DNA immunization
48. Immunization with a DNA expression vector encoding the varicella zoster virus glycoprotein E (gE) gene via intramuscular and subcutaneous routes
49. Varicella-zoster virus (VZV) ORF65 virion protein is dispensable for replication in cell culture and is phosphorylated by casein kinase II, but not by the VZV protein kinases
50. Granulysin blocks replication of varicella-zoster virus and triggers apoptosis of infected cells
51. Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen